샘플 요청 목록

 카트 문의
시장보고서
상품코드
1733908

세계의 그레이브스병(갑상선기능항진증) 시장

Graves Disease (Overactive Thyroid)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 386 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

그레이브스병(갑상선기능항진증) 세계 시장은 2030년까지 4억 8,710만 달러에 달할 전망

2024년에 3억 9,790만 달러로 추정되는 그레이브스병(갑상선기능항진증) 세계 시장은 2030년에는 4억 8,710만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 3.4%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 항갑상선제는 CAGR 3.7%를 기록하며 분석 기간 종료시에는 2억 970만 달러에 달할 것으로 예측됩니다. β 차단제 부문의 성장률은 분석 기간 동안 CAGR 3.0%로 추정됩니다.

미국 시장은 1억 840만 달러로 추정, 중국은 CAGR 6.4%로 성장 예측

미국의 그레이브스병(갑상선기능항진증) 시장은 2024년에 1억 840만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 9,710만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.3%와 2.7%로 예측됩니다. 유럽에서는 독일이 CAGR 2.0%로 성장할 것으로 예측됩니다.

그레이브스병(갑상선기능항진증) 시장 - 주요 동향과 촉진요인 정리

왜 그레이브스병이 전 세계적으로 공중보건 문제가 되고 있는 것일까?

전 세계 갑상선 기능 항진증의 주요 원인인 갑상선 기능 항진증은 유병률 증가, 과소 진단, 대사 건강에 미치는 심각한 영향 때문에 의료계의 관심이 높아지고 있습니다. 갑상선 자극 면역글로불린(TSI)에 의한 갑상선 호르몬의 과잉 생산이 특징인 이 자가면역질환은 여성에게 편중되어 있으며, 30-50세 사이에 발병하는 경우가 많습니다. 치료가 가능하지만, 관리하지 않고 방치하면 심혈관 스트레스, 골다공증, 안질환(갑상선안와증), 불임 등 심각한 합병증을 유발할 수 있습니다.

유전적 감수성, 환경적 요인, 생활습관의 변화로 인해 자가면역질환이 전 세계적으로 증가하고 있으며, 갑상선 질환은 더욱 각광을 받고 있습니다. 갑상선 관련 질환, 특히 여성 건강에 대한 인식이 높아지고 정기적인 갑상선 기능 검사도 발견율 향상에 기여하고 있습니다. 특히 자가면역성 갑상선 질환이 많은 북미, 유럽, 아시아 일부 지역에서는 공중 보건 기관이 갑상선 건강을 예방 의료 프로그램에 포함시키고 있습니다.

질병 관리를 개선하기 위해 진단 및 치료법은 어떻게 진화하고 있는가?

갑상선 자극 호르몬(TSH) 측정법, 방사성 요오드 흡수 검사, 항갑상선 항체 프로파일링의 보급으로 갑상선 기능 항진증의 진단 상황이 크게 개선되었습니다. 고해상도 갑상선 초음파 검사 및 방사성 핵종 스캔과 같은 영상 기술의 혁신으로 인해 현재 보다 정확한 병기 분류와 다른 갑상선 기능 항진증과의 감별이 가능해졌습니다. 특히 갑상선 결절이나 자가면역질환이 동반되어 임상 양상을 복잡하게 만드는 경우, 임상의가 적시에 정확한 치료 방침을 결정할 수 있게 되었습니다.

갑상선 질환의 치료법은 항갑상선제(메티마졸, 프로피르티오우라실 등), 방사성 요오드 치료(RAI), 갑상선 절제술의 세 가지 주요 경로를 따라 계속 발전하고 있습니다. 각각의 선택은 연령, 질병의 중증도, 임신 상태, 동반 질환 등 환자별 요인에 따라 결정됩니다. 최근 연구는 특히 간독성 및 무과립구증 위험과 관련하여 항갑상선 약물의 장기적인 안전성과 내약성을 개선하는 데 초점을 맞추고 있습니다. 이와 병행하여, 최소침습적 갑상선 수술과 방사성 요오드 표적 투여법의 발전으로 합병증이 감소하고 치료 후 삶의 질이 향상되고 있습니다. 현재 연구 중인 새로운 치료법으로는 TSH 수용체 항체를 표적으로 하는 생물학적 제제, 증상을 억제하는 것뿐만 아니라 질병의 경과를 변화시키는 것을 목표로 하는 면역조절제 등이 있습니다.

시장 수요를 형성하는 지역과 환자층은?

그레이브스병은 지역별로 유병률과 관리 패턴이 다릅니다. 북미는 높은 의료비 지출, 잘 구축된 내분비학 네트워크, 시민 인식 개선 캠페인에 힘입어 진단 및 치료 접근성 측면에서 시장을 선도하고 있습니다. 유럽은 영국과 독일과 같은 국가들이 탄탄한 검진 프로그램과 종합적인 자가면역질환 관리 체계를 갖추고 있어 그 뒤를 잇고 있습니다. 아시아태평양의 경우, 의료 인프라가 잘 갖추어져 있고, 도시 지역에서의 인식이 높아져 진단율 향상에 기여하고 있지만, 농촌 인구가 많아 내분비내과 전문의에 대한 접근성이 제한적입니다.

인구통계학적으로, 갑상선 질환으로 진단받은 환자의 75% 이상이 여성이며, 특히 생식기에 여성에 대한 건강검진 및 연구에 중점을 두고 있습니다. 또한, 갑상선 질환은 사춘기 및 폐경기 여성에게도 발병하는 경우가 많아 진단과 치료가 더욱 복잡해지고 있습니다. 또한, 갑상선 안질환의 경우, 장기적인 모니터링과 안과적 지원에 대한 수요로 인해 전문 의료 분야에서 보조 진단 및 수술적 개입을 위한 2차 시장이 형성되고 있습니다.

그레이브스병 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다 ...

그레이브스병 시장의 성장은 치료 프로토콜의 진화, 진단의 혁신, 내분비학 치료에 대한 접근성 확대와 직결되는 여러 요인에 의해 주도되고 있습니다. 기술적으로는 보다 민감한 면역 측정법, 정밀한 영상 진단 도구, 동반진단 키트의 개발로 질병을 감지하고 모니터링하는 능력이 크게 향상되었습니다. 이러한 발전은 위험을 최소화하고 장기적인 결과를 개선할 수 있는 맞춤형 치료 전략을 가능하게 합니다.

최종 용도 측면에서는 자가면역성 갑상선 질환의 부담 증가와 더불어 일반 대중의 인식 제고 및 정기적인 검진 실시로 인해 치료 대상이 확대되고 있습니다. 내분비학, 안과, 외과 전문 지식을 결합한 통합 갑상선 의료 모델의 출현은 고급 의료 서비스에 대한 수요를 더욱 증가시키고 있습니다. 또한, 신흥국의 의료비 지출 증가와 원격 내분비학 플랫폼의 성장으로 인해 이전에는 의료 서비스가 부족했던 지역의 의료 접근성이 향상되고 있습니다. 면역요법 및 질병 변형 약물에 초점을 맞춘 임상시험이 진행 중이며, 혁신적 치료 환경이 조성되고 있어 전 세계 그레이브스병 치료 시장이 지속적으로 확대될 것으로 보입니다.

부문

치료제(항갑상선제, 베타 차단제, 요오드 요법, 방사성 요오드 요법, 기타 치료제), 투여 경로(경구, 비경구, 기타 투여 경로), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례(총 47개사)

  • Abbott Laboratories
  • Apitope International NV
  • bioMerieux SA
  • Crinetics Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • HanAll Biopharma
  • Horizon Therapeutics(Amgen Inc.)
  • Immunovant, Inc.
  • Institute of Isotopes Co., Ltd.
  • Jubilant Pharma Holdings Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sling Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Tourmaline Bio
  • Viridian Therapeutics

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.11

Global Graves' Disease (Overactive Thyroid) Market to Reach US$487.1 Million by 2030

The global market for Graves' Disease (Overactive Thyroid) estimated at US$397.9 Million in the year 2024, is expected to reach US$487.1 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Anti-thyroid Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$209.7 Million by the end of the analysis period. Growth in the Beta Blockers segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$108.4 Million While China is Forecast to Grow at 6.4% CAGR

The Graves' Disease (Overactive Thyroid) market in the U.S. is estimated at US$108.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$97.1 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Graves' Disease (Overactive Thyroid) Market - Key Trends & Drivers Summarized

Why Is Graves' Disease Emerging as a Global Public Health Concern?

Graves' disease, the leading cause of hyperthyroidism worldwide, is gaining increasing attention from health systems due to its rising prevalence, underdiagnosis, and its significant impact on metabolic health. This autoimmune disorder, characterized by excessive thyroid hormone production due to thyroid-stimulating immunoglobulins (TSIs), disproportionately affects women and often manifests in individuals aged 30 to 50. Although treatable, if left unmanaged, it can lead to serious complications, including cardiovascular stress, osteoporosis, eye disease (Graves' orbitopathy), and fertility issues.

The global increase in autoimmune diseases, driven by genetic susceptibility, environmental triggers, and lifestyle changes, has pushed Graves' disease further into the spotlight. A heightened awareness of thyroid-related disorders, especially in women’s health, and routine thyroid function testing have also contributed to higher detection rates. Public health agencies are increasingly including thyroid health in their preventive care programs, particularly in North America, Europe, and parts of Asia where autoimmune thyroid conditions are more prevalent.

How Are Diagnostics and Treatment Modalities Evolving to Improve Disease Management?

The diagnostic landscape for Graves' disease has significantly improved, driven by the widespread availability of thyroid-stimulating hormone (TSH) assays, radioactive iodine uptake tests, and anti-thyroid antibody profiling. Innovations in imaging technology, such as high-resolution thyroid ultrasound and radionuclide scanning, now allow for more accurate disease staging and differentiation from other forms of hyperthyroidism. This has enabled clinicians to make timely and precise treatment decisions, especially in cases where thyroid nodules or coexisting autoimmune conditions complicate the clinical picture.

Treatment approaches for Graves' disease continue to evolve along three primary paths: antithyroid medications (like methimazole and propylthiouracil), radioactive iodine therapy (RAI), and thyroidectomy. Each option is selected based on patient-specific factors including age, disease severity, pregnancy status, and comorbidities. Recent studies have focused on improving the long-term safety and tolerability of antithyroid drugs, particularly regarding hepatotoxicity and agranulocytosis risks. In parallel, advancements in minimally invasive thyroid surgeries and targeted radioiodine dosing have reduced complications and improved post-treatment quality of life. Novel therapies under investigation include biologics targeting TSH receptor antibodies and immune modulators aimed at altering the disease course rather than just controlling symptoms.

Which Regions and Patient Demographics Are Shaping Market Demand?

Graves' disease exhibits varying prevalence and management patterns across regions. North America leads the market in terms of diagnosis and treatment accessibility, supported by high healthcare expenditure, established endocrinology networks, and public awareness campaigns. Europe follows closely, where countries like the UK and Germany have robust screening programs and comprehensive autoimmune disease management frameworks. In the Asia-Pacific region, rising healthcare infrastructure and increasing urban awareness are contributing to improved diagnosis rates, although large rural populations still face underdiagnosis and limited access to endocrine specialists.

Demographically, women account for over 75% of all diagnosed cases of Graves’ disease, particularly during reproductive years, prompting focused efforts in women's health screening and research. The condition is also increasingly observed in adolescents and perimenopausal women, creating additional layers of diagnostic and therapeutic complexity. Furthermore, the demand for long-term monitoring and ophthalmologic support in cases of thyroid eye disease is creating secondary markets for supportive diagnostics and surgical interventions in specialty care.

The Growth in the Graves’ Disease Market Is Driven by Several Factors…

The growth in the Graves’ disease market is driven by several factors directly tied to evolving treatment protocols, diagnostic innovation, and expanding access to endocrinological care. Technologically, the development of more sensitive immunoassays, refined imaging tools, and companion diagnostic kits has significantly improved disease detection and monitoring capabilities. These advancements enable personalized treatment strategies that minimize risks and enhance long-term outcomes.

On the end-use front, the increasing burden of autoimmune thyroid diseases, along with heightened public awareness and routine screening practices, is expanding the treatment population. The emergence of integrated thyroid care models-combining endocrinology, ophthalmology, and surgical expertise-is further boosting demand for advanced care services. Additionally, rising healthcare expenditure in emerging economies and the growth of tele-endocrinology platforms are improving access to care in previously underserved regions. With ongoing clinical trials focused on immunotherapies and disease-modifying drugs, the therapeutic landscape is poised for innovation, signaling continued expansion of the Graves’ disease treatment market globally.

SCOPE OF STUDY:

The report analyzes the Graves' Disease (Overactive Thyroid) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy, Other Treatments); Administration Route (Oral, Parenteral, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Apitope International NV
  • bioMerieux SA
  • Crinetics Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • HanAll Biopharma
  • Horizon Therapeutics (Amgen Inc.)
  • Immunovant, Inc.
  • Institute of Isotopes Co., Ltd.
  • Jubilant Pharma Holdings Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sling Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Tourmaline Bio
  • Viridian Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Graves' Disease (Overactive Thyroid) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Autoimmune Disorders Propels Demand for Graves Disease Diagnosis and Treatment
    • Increased Awareness and Early Screening Programs Expand the Addressable Patient Base
    • Advancements in Diagnostic Imaging and Antibody Testing Drive Adoption of Precision Diagnostics
    • Growth in Thyroid Function Test Utilization Enhances Early Detection Rates for Graves Disease
    • Development of Targeted Therapies and Biologics Strengthens the Treatment Pipeline
    • Expansion of Telehealth and Endocrinology Consultations Accelerates Diagnosis in Underserved Areas
    • Patient Education Initiatives Throw the Spotlight on Symptom Recognition and Early Intervention
    • Growing Geriatric Population Increases Prevalence of Thyroid Dysfunctions and Treatment Demand
    • Innovation in Radioactive Iodine Therapy and Dosimetry Improves Patient Outcomes and Safety
    • Surgical Advancements and Minimally Invasive Techniques Drive Treatment Option Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Graves' Disease (Overactive Thyroid) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-thyroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-thyroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Anti-thyroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Iodine Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radioactive Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radioactive Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Radioactive Iodine Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제